Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens-Reference-Cited by-同舟云学术

Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens

Published:2022-04-20 Issue:5 Volume:22 Page:505-522
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Johnson Kai CC¹,Quiroga Dionisia¹²,Sudheendra Preeti¹,Wesolowski Robert¹²

Affiliation:

1. Department of Internal Medicine, Division of Medical Oncology, Stefanie Spielman Comprehensive Breast Center, Columbus, OH, USA

2. Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2063844

Reference98 articles.

1. The basic biology of HER2

2. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

3. HER2 expression status in diverse cancers: review of results from 37,992 patients

4. HER2-targeted therapies — a role beyond breast cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer;npj Breast Cancer;2024-06-19

2. Alkaloids as Additional Weapons in the Fight against Breast Cancer: A review;Current Medicinal Chemistry;2023-09-11

3. An update on the pathological classification of breast cancer;Histopathology;2022-12-08